- Home
- PAGP vs TVTX Comparison
PAGP vs TVTX Comparison
Compare PAGP & TVTX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PAGP | TVTX |
|---|---|---|
| Founded | 2013 | N/A |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Natural Gas Distribution | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | PAGP | TVTX |
|---|---|---|
| Price | $23.76 | $27.13 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 8 | 13 |
| Target Price | $20.71 | ★ $36.25 |
| AVG Volume (30 Days) | ★ 1.8M | 1.3M |
| Earning Date | 05-08-2026 | 05-11-2026 |
| Dividend Yield | ★ 7.05% | N/A |
| EPS Growth | ★ 370.00 | 92.89 |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $44,262,000,000.00 | N/A |
| Revenue This Year | $18.63 | $44.62 |
| Revenue Next Year | $1.04 | $32.09 |
| P/E Ratio | $87.70 | ★ N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $16.61 | $12.91 |
| 52 Week High | $23.70 | $42.13 |
Technical Indicators
Market Signals| Indicator | PAGP | TVTX |
|---|---|---|
| Relative Strength Index (RSI) | 84.15 | 36.30 |
| Support Level | $18.53 | $27.01 |
| Resistance Level | N/A | $31.47 |
| Average True Range (ATR) | 0.33 | 1.42 |
| MACD | 0.13 | -0.15 |
| Stochastic Oscillator | 90.12 | 13.74 |
Price Performance
Historical ComparisonAbout PAGP Plains GP Holdings L.P. Units representing Limited Partner Interests
Plains GP Holdings LP provides transportation, storage, processing, fractionation, and marketing services for crude oil, refined products, natural gas liquids, liquefied petroleum gas, and related products. The group manages its operations through two operating segments: Crude Oil and NGL.
About TVTX Travere Therapeutics Inc.
Travere Therapeutics Inc is a biopharmaceutical company. The company is focused on identifying, developing and delivering life-changing therapies to people living with rare kidney, liver, and metabolic diseases. Its pipeline candidate, sparsentan, is an investigational product candidate in late-stage development for focal segmental glomerulosclerosis (FSGS) and IgA nephropathy (IgAN)-rare kidney disorders that often cause end-stage kidney disease.